Product Description
Mechanisms of Action: PR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Vaginal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Indonesia | Ireland | Italy | Latvia | Lithuania | Luxembourg | Malta | Mexico | Morocco | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Organon
Company Location: JERSEY CITY NJ 07302
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Contraception|Thrombophilia|Uterine Diseases|Healthy Volunteers
Phase 3: Contraception
Phase 2: Injuries/wounds Unspecified|Uterine Hemorrhage|Contraception
Phase 1: Other|Contraception|Noma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Inclusive | P3 |
Terminated |
Contraception |
2024-01-12 |
|
| ZOEPREP | P4 |
Completed |
Uterine Diseases |
2023-08-01 |
|
| DROVZOEFFIPREP | P4 |
Completed |
Uterine Diseases |
2023-08-01 |
|
| ESTNMG-04-GRU | P1 |
Withdrawn |
Other |
2019-12-01 |